You are here: Industry Insights > Mirikizumab

News List

Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study drugs
July 16, 2021
Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year.
Lilly’s mirikizumab hits primary endpoint in ulcerative colitis study pharmatimes
March 18, 2021
Eli Lilly’s anti-IL-23p19 monoclonal antibody (mAb) mirikizumab has met the primary endpoint and all key secondary endpoints in a Phase III ulcerative colitis (UC) study.
Lilly’s mirikizumab superior to Cosentyx in phase 3 study for patients with moderate to severe plaque psoriasis pharmaceutical-business-review
July 22, 2020
Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and ...
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions drugs
May 30, 2019
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions.
Mirikizumab Met Primary, Secondary Endpoints in Phase 2 Studies americanpharmaceuticalreview
May 23, 2019
Eli Lilly and Company has announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease.